Newborn bloodspot screening
Policy and guidelines

Contacts.......................................................................................................................................................... 2
Background.................................................................................................................................................. 3
Roles and responsibilities for newborn bloodspot screening................................................................. 4
Newborn bloodspot screening guidelines for service providers ............................................................... 5
  Informing parents about screening ........................................................................................................ 5
  Written consent for screening ............................................................................................................. 5
  Decline of screening ............................................................................................................................. 6
  Sample collection ................................................................................................................................... 6
  Screening results and follow up ............................................................................................................. 6
Appendix 1: List of newborn bloodspot screening conditions ................................................................. 8
Appendix 2: Relevant legislation and guidelines .................................................................................... 9
Contacts

Detailed newborn bloodspot screening program information including brochures and the e-learning tool for maternity providers are available at: www.vcgs.org.au/nbs

Newborn Bloodspot Screening Laboratory
PO Box 1100, Parkville 3052

Laboratory Operation Hours:
Monday to Friday 0730 and 1730 (excluding public holidays)

Result and sample enquiries:
• phone: (03) 8341 6272
• fax: (03) 8341 6339
• email: screeninglab@vcgs.org.au

Parent counselling enquiries: phone: (03) 8341 6200

A video about the Victorian newborn bloodspot screening laboratory is available at www.vcgs.org.au/nbs

Department of Health and Human Services, Screening and Preventive Health Services
• phone: (03) 9096 0482
• email: evidence.evaluation@dhhs.vic.gov.au

If you would like to receive this publication in an accessible format, please phone 03 9096 0395 using the National Relay Service 13 3677 if required, or email: evidence.evaluation@dhhs.vic.gov.au.

This document is also available in PDF format on the internet at:

Published by Prevention and Population Health Branch

Victorian Government Department of Health and Human Services, Melbourne, Victoria

© Copyright, State of Victoria, Department of Health and Human Services, 2018

This publication is copyright, no part may be reproduced by any process except in accordance with the provisions of the Copyright Act 1968.

Authorised by the State Government of Victoria, 50 Lonsdale Street, Melbourne.
Key points

• Newborn bloodspot screening must be offered to parents\(^1\) of all babies born in Victoria.

• To support informed decision making, parents are to be given written and verbal information prior to screening, ideally in the third trimester of pregnancy.

• Written consent for screening must be obtained before a blood sample is collected from the baby.

• Hospitals and service providers\(^2\) are responsible for ensuring that a completed screening card is submitted to the Newborn Bloodspot Screening Laboratory for all births, including for those babies whose parents did not provide consent.

• Hospitals and service providers are responsible for ensuring that all births have either a screening result recorded or a completed decline form in the mother’s medical record.

• Employers are responsible for ensuring that staff are aware of their role and responsibilities in relation to newborn bloodspot screening and are competent to undertake the task.

Background

Newborn bloodspot screening (NBS) is an important public health program that facilitates the early identification and management of babies at risk of having rare but serious medical conditions that can affect normal development. This program has been available to all babies born in Victoria since the late 1960s. The program is funded by the Victorian Department of Health and Human Services, which contracts the Victorian Clinical Genetics Services (VCGS) to operate the Newborn Bloodspot Screening Laboratory. The laboratory is located at The Royal Children’s Hospital in Melbourne.

Screening is a quick, safe and effective way to identify newborns at risk of having a rare but serious medical condition. Early identification allows for early intervention (usually with diet and/or medication) and can lead to a significant reduction in morbidity and mortality for affected infants.

Currently, conditions that can be identified through newborn bloodspot screening include phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis (CF) and approximately 22 other metabolic conditions that affect fat or protein metabolism (Appendix 1).

Screening is conducted using a small blood sample obtained by pricking the baby’s heel, 48–72 hours after birth. This sample is collected onto an absorbent paper card and is processed at the Newborn Bloodspot Screening Laboratory in Melbourne.

Parents are required to provide written consent for newborn bloodspot screening prior to the blood sample being taken.

Storage and access to the screening cards are governed by a number of pieces of state legislation (Appendix 2). All screening cards collected in public facilities, private institutions or at home in Victoria are considered public records under the Public Records Act 1973.

---

\(^1\) Or legal guardians

\(^2\) Including independent midwives
The newborn bloodspot screening cards must be stored by the laboratory for a period of two years in line with National Pathology Accreditation Advisory Council (NPAAC) guideline. This allows further clinical testing if needed and is also a requirement for laboratory quality control. Currently, after the two-year period of laboratory storage all cards are stored indefinitely in a secure, off-site facility.

Parents and individuals 18 years or older have the right to request transfer of the card to them after it has been stored for a minimum of two years by approaching the Victorian Bloodspot Screening Laboratory directly.

In line with state legislation, stored cards may be accessed by Victoria Police with a court order and by the coroner. Cards may also be used for ethics approved, de-identified research, subject to the parents' consent. Identified cards may be accessed for research use only with the consent of the parents.

At the time of sample collection, parents have the right to specify that the sample is not available for de-identified research use.

Roles and responsibilities for newborn bloodspot screening

The following section outlines the key responsibilities of stakeholders involved in newborn bloodspot screening. Further information is available in the Newborn Bloodspot Screening National Policy Framework 2018.

Department of Health and Human Services

- program funding
- policy and program development
- program monitoring, including quality improvement, evaluation and review

Hospital/maternity service provider

- development of hospital policies to support newborn bloodspot screening program timeliness, quality and safety
- provision of information to parents
- ensure all parents are offered screening
- appropriate record keeping – screening result or decline for all births
- support continuing education for midwives about newborn bloodspot screening
- assign responsibility for newborn bloodspot screening to two individuals who will:
  - be available from Monday to Friday via email
  - be the first point of contact for the laboratory
  - ensure timely delivery of screening cards to the laboratory
  - ensure every birth has a screening result or a decline form on file
  - ensure that the secure electronic recollection letters are followed up daily
Midwife

- provision of information and discussion in relation to bloodspot screening with parents
- offer of screening
- obtain written consent
- appropriate sample collection
- record refusal – sign hospital decline form and generate a card for the laboratory

Newborn Bloodspot Screening Laboratory

- timely screening of all samples received
- timely reporting of results to all hospitals/providers
- timely requests for repeat samples made to hospital/provider
- timely contact with hospital/clinical specialist to arrange diagnostic testing if required
- provision of regular feedback to hospitals/providers in terms of consent compliance, timeliness issues and sample quality

Newborn bloodspot screening guidelines for service providers

Informing parents about screening

Before sample collection, staff must ensure parents are properly informed about screening and its importance.

The information brochure Newborn bloodspot screening: for the health of your baby should be provided to parents during the last trimester. The information must be discussed with parents and is available in a number of community languages at: www.vcgs.org.au/tests/newborn-screening

Hospitals/providers must ensure parents\(^3\) of all newborns are offered screening.

Written consent for screening

Implied consent for screening is inadequate. Staff must obtain written consent from a parent prior to sample collection. Written consent is provided by reading and signing a section of the screening card.

After reading the brochure and discussing the test with their midwife, one parent is to complete the consent section on the card. This section also allows parents to indicate their preference with regard to the secondary use of the screening card in de-identified health research.

Making screening cards available for research use is a personal choice and should not deter parents from having their baby screened.

\(^3\) Or legal guardians
• Parents have the right to request that the card is not available for research use.

• In addition, parents should be informed of their ability to request transfer of the screening card after a period of two years.

Decline of screening

While newborn bloodspot screening is strongly recommended for all babies, it is a voluntary program in Australia. If parents wish to decline screening, it is important to discuss their reasons and ensure they are aware of the risks (with referral to a paediatrician or newborn bloodspot screening counsellor at the Victorian laboratory if necessary). If parents choose to decline, a signed screening card indicating that the test was declined must be provided to the laboratory. A hospital record of decline must also be signed by the parent and filed in the medical record.

• A screening card must be sent to the laboratory – this is a record that parents were offered, and declined screening. The laboratory is not aware of a birth until they receive a screening card. This is an important record for the laboratory.

• A decline of screening form must be signed and kept in the mother’s record – this is the equivalent hospital record that screening was declined.

Sample collection

Newborn bloodspot screening is carried out using a blood sample obtained by pricking the baby’s heel, 48–72 hours after birth. Inaccurate results can occur when the sample is collected outside these times. Screening cards must be sent daily via pathology courier / courier or Express Post to the screening laboratory, after air-drying.


More information is available in the newborn bloodspot screening e-learning tool for midwives and administrative staff at: https://www.vcgs.org.au/newborn-screening

A video about the Victorian newborn bloodspot screening laboratory is available at https://vimeo.com/277932326/575f7e6103

Screening results and follow up

The Newborn Bloodspot Screening Laboratory will issue a report of results on a weekly basis (electronic) to all hospitals/providers. Parents will not be contacted when screening results are normal but this may take a few weeks. Positive screens will be followed up immediately with parents and the associated hospital/paediatrician by clinical staff from VCGS/The Royal Children’s Hospital or Monash Medical Centre once contact details for parents are obtained from the maternity provider.

A repeat collection will be requested by the laboratory for inadequate/contaminated samples/missing data or samples giving borderline abnormal results. The request will be sent by secure electronic mail to the two hospital/provider nominated with the NBS lab. While concerning for some parents, reassurance should be given that repeat samples usually return a normal result.

---

4 including independent midwives
Each hospital must identify two newborn bloodspot screening liaison people. These individuals will be the first point of contact for the laboratory. In particular, these persons will be responsible for handling requests for repeat samples and will be required to check that the weekly report of screening results from the laboratory matches the hospital birth record.

- It is the responsibility of all hospitals to make certain every birth is accounted for.
- There may be legal implications for hospitals if appropriate records are not maintained.

5 Independent midwives will work directly with laboratory staff.
### Appendix 1: List of newborn bloodspot screening conditions

<table>
<thead>
<tr>
<th>#</th>
<th>Disorder</th>
<th>Other names</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Cystic fibrosis</td>
<td></td>
</tr>
</tbody>
</table>

**Disorders detected by tandem mass spectrometry:**

<table>
<thead>
<tr>
<th>#</th>
<th>Disorder</th>
<th>Other names</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>3-hydroxy-3-methylglutaryl CoA lyase</td>
<td>HMG CoA lyase</td>
</tr>
<tr>
<td>4</td>
<td>3-methylglutaryl CoA hydratase</td>
<td>3-methylglutaconic aciduria type 1</td>
</tr>
<tr>
<td>5</td>
<td>Argininosuccinic aciduria</td>
<td>Argininosuccinate lyase</td>
</tr>
<tr>
<td>6</td>
<td>Citrullinaemia type 1</td>
<td>Argininosuccinate synthetase</td>
</tr>
<tr>
<td>7</td>
<td>Beta ketothiolase</td>
<td>T2 deficiency, 3-oxothiolase</td>
</tr>
<tr>
<td>8</td>
<td>Maple syrup urine disease</td>
<td>MSUD, branched chain keto acid dehydrogenase (mild/intermittent forms may not be detected)</td>
</tr>
<tr>
<td>9</td>
<td>Carnitine palmitoyl transferase 1</td>
<td>CPT1</td>
</tr>
<tr>
<td>10</td>
<td>Carnitine palmitoyl transferase 2</td>
<td>CPT2</td>
</tr>
<tr>
<td>11</td>
<td>Carnitine uptake defect</td>
<td>CUD, systemic carnitine deficiency, carnitine transporter defect, OCTN2 defect</td>
</tr>
<tr>
<td>12</td>
<td>Carnitine-acyl carnitine translocase</td>
<td>CACT</td>
</tr>
<tr>
<td>13</td>
<td>Cobalamin disorders</td>
<td>cbC, cbD, cbF disease</td>
</tr>
<tr>
<td>14</td>
<td>Homocystinuria</td>
<td>Cystathionine betasynthase, CBS (vitamin responsive forms may not be detected)</td>
</tr>
<tr>
<td>15</td>
<td>Glutaric aciduria type 1</td>
<td>Glutaryl CoA dehydrogenase, GA1</td>
</tr>
<tr>
<td>16</td>
<td>Holocarboxylase synthase</td>
<td>HCS, multiple carboxylase deficiency, MCD</td>
</tr>
<tr>
<td>17</td>
<td>Isovaleryl CoA dehydrogenase</td>
<td>Isovaleric acidemia, IA</td>
</tr>
<tr>
<td>18</td>
<td>Medium-chain acyl CoA dehydrogenase</td>
<td>MCAD</td>
</tr>
<tr>
<td>19</td>
<td>Methylmalonic acidemia</td>
<td>Methylmalonyl CoA mutase, MMA, cbIA, cbIB disease</td>
</tr>
<tr>
<td>20</td>
<td>Mitochondrial trifunctional protein</td>
<td>Long-chain hydroxy acyl carnitine dehydrogenase, LCHAD, MTP</td>
</tr>
<tr>
<td>21</td>
<td>Multiple acyl CoA dehydrogenase</td>
<td>MADD, glutaric aciduria type 2, GA2, ETF deficiency</td>
</tr>
<tr>
<td>22</td>
<td>Phenylketonuria</td>
<td>PKU, phenylalanine hydroxylase, including tetrahydrobiopterin defects</td>
</tr>
<tr>
<td>23</td>
<td>Propionic acidemia</td>
<td>Propionyl CoA carboxylase, PA, ketotic hyperglycaemia</td>
</tr>
<tr>
<td>24</td>
<td>Tyrosinaemia 2</td>
<td>Tyrosine aminotransferase</td>
</tr>
<tr>
<td>25</td>
<td>Very long chain acyl CoA dehydrogenase</td>
<td>VLCAD</td>
</tr>
</tbody>
</table>

NB: other disorders are occasionally detected as part of the newborn screening testing, including disorders affecting the mother, which will be followed-up and referred as defined by the relevant NBS standard operating protocols.
Appendix 2: Relevant legislation and guidelines

In various ways, the following pieces of legislation apply to the newborn screening cards and the blood samples and data derived from them. This legislation governs storage of the cards, access during storage and also their appropriate disposal.

*Health Records Act 2001 (Vic)* – screening cards are ‘health information’ for the purposes of the health records act.

*Privacy and Data Protection Act 2014 (Vic) Privacy Act 1988 (Cth)*

*Public Records Act 1973 (Vic)* – all screening cards collected in public and private institutions are classified as public records.

*Human Tissue Act 1982 (Vic)*

National Pathology Accreditation Advisory Council (NPAAC). Requirements for the Retention of Laboratory Records and Diagnostic Material (Seventh Edition 2018).
